About me2021 (ongoing) - Coordinator for clinical competences in the Curriculum Committee of the Medicine Programme of the Karolinska Institutet 2020 (ongoing) - Director of studies for the elective courses in the Medicine Programme of the Karolinska Institutet 2020 (ongoing) - Member of the Delegation for Education of the Swedish Society of Medicine 2020 (ongoing) - Member of the working group for Interprofessional Learning Environments, Region Stockholm 2019 (ongoing) - Assistant Director of Studies for the Internal Medicine course in the Medicine Programme of the Karolinska Institutet 2018 (ongoing) - Responsible for the elective course "Acute and chronic inflammation", Karolinska Institutet 2018 (ongoing) - Promoter for Interprofessional Education, Karolinska Institutet 2017 (ongoing) - Convener for national working group for rheumatology learning outcomes for undergraduates within the frame of the Swedish Society for Rheumatology 2017 (ongoing) - Responsible for the course for rheumatology residents "Inflammatory systemic diseases", Karolinska Institutet/Karolinska University Hospital 2015 (ongoing) - Responsible for the clinical rotation "Inflammatory diseases" (LINK/ERASMUS), Karolinska Institutet 2015 to 2020 - Responsible for the rheumatology rotation for undergraduates, Karolinska University Hospital
Clinical and translational research within the field of inflammation and autoimmunity.
The goal of my research is to contribute to improved surveillance and management for people living with systemic lupus erythematosus. I focus on identification of biomarkers that reflect activity and portend flare, response or non-response to therapy, particularly B cell targeted biologics, and long-term outcome. I stress on patient-reported health status and patient participation in medical care. Last but not least, I am involved in projects within medical pedagogy; we are currently working on the development of a novel virtual patient modality for interprofessional learning.
Systemic lupus erythematosus: biomarkers and biologics
Defence: 17 February 2017
Main supervisor: Iva Gunnarsson
Co-supervisors: Vivianne Malmström, Agneta Zickert, Ronald van Vollenhoven
Opponent: Frédéric Houssiau
Peer-reviewed original articles
Submitted; not yet acceptedChalmers S, Rajalakshmi Ramachandran R, Garcia S, Der E, Herlitz L, Ampudia J, Zhang T, Parodis I, Gunnarsson I, Ding H, Shen N, Petri M, Mok C, Saxena R, Polu K, Connelly S, Ng C, Mohan C, Putterman C. The CD6-ALCAM pathway promotes lupus nephritis via T cell mediated responses. [Under review] Hernández-Breijo B, Navarro-Compán V, Plasencia-Rodríguez C, Parodis I, Gehin JE, Martínez-Feito A, Novella-Navarro M, Mezcua A, Warren DJ, Nozal P, Pascual-Salcedo D, Balsa A. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. [Under review] Gomez A, Qiu V, Cederlund A, Borg A, Lindblom J, Emamikia S, Enman Y, Lampa J, Parodis I. Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. [Under review] Lindblom J, Gomez A, Borg A, Emamikia S, Ladakis D, Matilla J, Pehr M, Enman Y, Heintz E, Regardt M, Parodis I. EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus. [Revised manuscript under review]
Published/acceptedBorg A, Gomez A, Cederlund A, Cobar F, Qiu V, Lindblom J, Emamikia S, Enman Y, Pettersson S, Parodis I. Contribution of abnormal BMI to adverse health-related quality of life outcomes following treatment in systemic lupus erythematosus. Rheumatology (Oxford). 2021 [Epub ahead of print] Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology (Oxford). 2019 Dec 1;58(12):2170-2176
Submitted; not yet acceptedSciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, Pons-Estel G, Mosca M. Pre-Lupus, Early-Lupus, or undifferentiated connective tissue disease? [Revised manuscript under review]
PublishedParodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020 Feb 18;7(1):e000389. doi: 10.1136/lupus-2020-000389
Other scientific worksParodis I, Sjöwall C, Weiner M. [Lupus nephritis] (Article in Swedish). Bulletinen: Swedish Rheumatism Association. 2020; 4 Parodis I. [News about Benlysta] (Article in Swedish). Bulletinen: Swedish Rheumatism Association. 2019; 3 Parodis I, Dani L, Notarnicola A, Martenhed G, Fernström P, Matikas A, Wiklander O. [Drug-induced aortitis] (Article in Swedish). ReumaBulletinen: Swedish Society for Rheumatology. 2019; 1 Parodis I. Expert view: Refining the use of belimumab in SLE. 2019 Apr; Hospital Healthcare Europe